Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy AMAG Pharmaceuticals stock | 13.75

Own AMAG Pharmaceuticals stock in just a few minutes.


Fact checked

AMAG Pharmaceuticals, Inc is a biotechnology business based in the US. AMAG Pharmaceuticals shares (AMAG) are listed on the NASDAQ and all prices are listed in US Dollars. AMAG Pharmaceuticals employs 440 staff and has a trailing 12-month revenue of around USD$297.7 million.

How to buy shares in AMAG Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for AMAG Pharmaceuticals. Find the stock by name or ticker symbol: AMAG. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until AMAG Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$13.75, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of AMAG Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of AMAG Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted AMAG Pharmaceuticals's share price?

Since the stock market crash in March caused by coronavirus, AMAG Pharmaceuticals's share price has had significant positive movement.

Its last market close was USD$13.75, which is 30.91% up on its pre-crash value of USD$9.5 and 211.79% up on the lowest point reached during the March crash when the shares fell as low as USD$4.41.

If you had bought USD$1,000 worth of AMAG Pharmaceuticals shares at the start of February 2020, those shares would have been worth USD$624.85 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,539.73.

AMAG Pharmaceuticals share price

Use our graph to track the performance of AMAG stocks over time.

AMAG Pharmaceuticals shares at a glance

Information last updated 2020-10-20.
Latest market close USD$13.75
52-week range USD$4.41 - USD$13.8
50-day moving average USD$10.9168
200-day moving average USD$9.0227
Wall St. target price USD$11.96
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-6.826

Buy AMAG Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy AMAG Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

AMAG Pharmaceuticals price performance over time

Historical closes compared with the close of $13.75 from 2020-11-16

1 week (2020-11-19) N/A
1 month (2020-10-30) 0.22%
3 months (2020-08-28) 33.62%
6 months (2020-05-29) 78.34%
1 year (2019-11-29) 29.11%
2 years (2018-11-29) -23.10%
3 years (2017-11-29) 0.36%
5 years (2015-11-27) -48.98%

Is AMAG Pharmaceuticals under- or over-valued?

Valuing AMAG Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AMAG Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

AMAG Pharmaceuticals's PEG ratio

AMAG Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.32. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into AMAG Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

AMAG Pharmaceuticals financials

Revenue TTM USD$297.7 million
Gross profit TTM USD$177.7 million
Return on assets TTM -6.6%
Return on equity TTM -69.13%
Profit margin -86.95%
Book value $7.234
Market capitalisation USD$470.6 million

TTM: trailing 12 months

Shorting AMAG Pharmaceuticals shares

There are currently 10.1 million AMAG Pharmaceuticals shares held short by investors – that's known as AMAG Pharmaceuticals's "short interest". This figure is 0.2% down from 10.2 million last month.

There are a few different ways that this level of interest in shorting AMAG Pharmaceuticals shares can be evaluated.

AMAG Pharmaceuticals's "short interest ratio" (SIR)

AMAG Pharmaceuticals's "short interest ratio" (SIR) is the quantity of AMAG Pharmaceuticals shares currently shorted divided by the average quantity of AMAG Pharmaceuticals shares traded daily (recently around 458278.80704925). AMAG Pharmaceuticals's SIR currently stands at 22.13. In other words for every 100,000 AMAG Pharmaceuticals shares traded daily on the market, roughly 22130 shares are currently held short.

However AMAG Pharmaceuticals's short interest can also be evaluated against the total number of AMAG Pharmaceuticals shares, or, against the total number of tradable AMAG Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AMAG Pharmaceuticals's short interest could be expressed as 0.29% of the outstanding shares (for every 100,000 AMAG Pharmaceuticals shares in existence, roughly 290 shares are currently held short) or 0.6131% of the tradable shares (for every 100,000 tradable AMAG Pharmaceuticals shares, roughly 613 shares are currently held short).

A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against AMAG Pharmaceuticals.

Find out more about how you can short AMAG Pharmaceuticals stock.

AMAG Pharmaceuticals share dividends

We're not expecting AMAG Pharmaceuticals to pay a dividend over the next 12 months.

Have AMAG Pharmaceuticals's shares ever split?

AMAG Pharmaceuticals's shares were split on a 3:2 basis on 26 September 1991. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your AMAG Pharmaceuticals shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for AMAG Pharmaceuticals shares which in turn could have impacted AMAG Pharmaceuticals's share price.

AMAG Pharmaceuticals share price volatility

Over the last 12 months, AMAG Pharmaceuticals's shares have ranged in value from as little as $4.41 up to $13.8. A popular way to gauge a stock's volatility is its "beta".

AMAG.US volatility(beta: 1.03)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AMAG Pharmaceuticals's is 1.0265. This would suggest that AMAG Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

AMAG Pharmaceuticals overview

AMAG Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, and anemia management in the United States. The company markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women. Its product candidates also include AMAG-423 (ovine), an antibody fragment, which is in Phase 2b/3a trial for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent that is in planned Phase 2b trial for the treatment of novel oral anticoagulants or low molecular weight heparin. The company sells Feraheme to authorized wholesalers and specialty distributors. The company has license agreements with Endoceutics, Inc., Palatin Technologies, Inc., Velo Bio, LLC, Prasco, LLC, Perosphere Pharmaceuticals Inc., and Antares Pharma, Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site